The PTSD Checklist for DSM-5 (PCL-5) is a 20-item instrument that can be used to make a provisional diagnosis of PTSD based on DSM-5 criteria.
Active? Yes
First used: 14 October 2021
Related Topic
PTSDPTSD is generally grouped alongside anxiety disorders given the similar symptomology that is experienced. There is estimated to be over 300 million people living with PTSD globally. MDMA holds significant promise for treating PTSD and is in Phase III of the clinical trial process,
Related Papers
Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trialThis Phase II, nonrandomized open-label trial (n=22) tested a single 25 mg dose of psilocybin with psychological support in adults with PTSD. It found the treatment to be safe and well-tolerated, with common side effects such as headache, nausea, crying, and fatigue resolving quickly. Clinically meaningful reductions in PTSD symptoms were observed at weeks 4 and 12, alongside improvements in functioning and quality of life.
Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series
This study retrospectively analyzed clinical outcomes in 15 veterans with comorbid treatment-resistant depression (TRD) and PTSD who initially received intranasal ketamine treatment before sitting to treatment with IV racemic ketamine. Both treatments led to significant reductions in measures of TRD and PTSD however, treatment with IV racemic ketamine led to greater reductions, suggesting that off-label use of IV racemic ketamine may be useful for those who do not respond adequately to FDA-approved intranasal ketamine.
Related Trials
Frontline Clinician Psilocybin StudyWe aim to investigate the effects of a single dose of psilocybin, delivered in the context of pre- and post-dose psychotherapy, on symptoms of depression and burnout suffered by healthcare clinicians as a result of frontline work in the coronavirus disease of 2019 (COVID) pandemic.
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
This multi-site open-label study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in participants who were enrolled in a parent study for the treatment of posttraumatic stress disorder (PTSD).